by Simon Rodwell | 13 August 2013 10:15
The final results of this major clinical trial were announced in June 2017 at the American Society of Clinical Oncology (ASCO) conference in Chicago.
Dr Pippa Corrie, AVAST-M Trial Chief Investigator, comments:
‘I would like to renew our thanks to all those who took part in the AVAST-M trial. Although the results confirm that Avastin should not become a standard treatment after melanoma surgery, we have learned a great deal through this clinical trial and these conclusions will help shape the future of melanoma treatments.
‘The contribution of those who participated in AVAST-M was thoroughly worthwhile and will benefit others suffering from this disease in future’.
Please see The AVAST-M Patient Newsletter for further details
Source URL: https://melanomafocus.com/information-portal/avastm-trial-final-results/
Copyright ©2018 Melanoma Focus unless otherwise noted.